The FDA has issued a request for information (RFI) inviting public comments, particularly from veterinarians, regarding the use of cannabis-derived products (CDPs) in animals. This initiative focuses on cannabidiol (CBD) and other hemp-derived products, aiming to gather real-world insights to address critical data gaps about their safety and effectiveness.
While limited research on the use of CDPs in animals exists, significant uncertainties remain regarding various aspects of these products. The FDA is particularly interested in understanding veterinarians’ experiences, including:
- Patterns of use (species, brands, formulations, doses, and indications for use)
- Observed benefits and quality standards
- Potential drug interactions and adverse events
- Safety concerns and toxicological risks
Veterinarians’ input is essential to help shape the regulatory approach and encourage further research into the safety and efficacy of these products.
The RFI’s comment period opens on January 16, 2025, and remains open for 90 days, closing on April 16, 2025. All comments will be fully considered, and submissions may be made anonymously. For instructions on how to submit your comments, visit the Federal Register notice.
Veterinarians are encouraged to share their invaluable real-world experiences to help inform the FDA’s understanding of CDPs in animals. This is a unique opportunity to contribute to the development of safer, evidence-based guidelines for the use of these products in veterinary medicine.
For additional questions or concerns, reach out to the FDA directly.
